Program
Interferon Beta-1a Inhalation Solution SNG001
Its studies are mostly in COVID-19 · Pneumonia, Viral, led by Synairgen Research.
Furthest: phase 3, since Jan 28, 20213 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Synairgen Research | 30 open or running | phase 3since Jan 28, 2021 | Apr 24, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 24, 2020First study: phase 2 study in COVID-19First studyNCT04385095 · 221 enrolled · United Kingdom
- Jan 28, 2021Phase 3 study in COVID-19NCT04732949 · 623 enrolled · United States, Argentina, Belgium and more
- May 22, 2025Phase 2 study in Pneumonia, ViralNCT06999603 · 11 enrolled · United States, United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06999603Pneumonia, Viral · United States, United Kingdom | 2 | Terminated | Mar 13, 2026 | 11 |
| NCT04732949COVID-19 · United States, Argentina, Belgium and more | 3 | Completed | Dec 15, 2021 | 623 |
| NCT04385095COVID-19 · United Kingdom | 2 | Completed | Feb 17, 2021 | 221 |
How it is read
Names in the registry
- “SNG001”, 3 entries
Conditions, from the studies’ own filings
- COVID-19, 2 studies
- Pneumonia, Viral, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.